SCHEMBL23367281

SCHEMBL23367281

CCOC(=O)C(/C=N/O)=N/Nc1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 7/20 0.41
DHODH Q02127 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 3/20 0.40
LMNA P02545 4/20 0.39
PLK1 P53350 1/20 0.39
ATM Q13315 2/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 4/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 2/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29873957 1.00 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL29873542 0.90 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL23384999 0.90 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL29874396 0.87 SMN1; SMN2 (0.43) SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL23354854 0.87 GAA (0.52) SMN1; SMN2NPC1ALDH1A1CYP1A2CYP2C19
SCHEMBL23367559 0.87 SMN1; SMN2 (0.43) SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL23354856 0.87 GAA (0.52) SMN1; SMN2NPC1ALDH1A1CYP1A2CYP2C19
SCHEMBL23367414 0.87 GAA (0.52) SMN1; SMN2NPC1ALDH1A1CYP1A2CYP2C19
SCHEMBL23367283 0.85 MAPT (0.44) SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL23367387 0.85 MAPT (0.41) SMN1; SMN2RAB9AALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
WO-2021094434-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822265-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer AG (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAMTS1 SMN1; SMN2 3772/4885NPC1 3408/4885RAB9A 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.